ArticleBMC systems biology2013
Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer.
Article in BMC systems biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Gastric Cancer Associated Genes Identified by an Integrative Analysis of Gene Expression Data.BioMed research international · 2017Pooled it
- Review
- The fourth scientific discovery paradigm for precision medicine and healthcare: Challenges ahead.Precision clinical medicine · 2021Article
- MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation.Clinical and translational medicine · 2021Article
- Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies.Frontiers in pharmacology · 2021Review
- Data-driven translational prostate cancer research: from biomarker discovery to clinical decision.Journal of translational medicine · 2020Review
- Translational Informatics for Parkinson's Disease: from Big Biomedical Data to Small Actionable Alterations.Genomics, proteomics & bioinformatics · 2019Review
- Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.Journal of translational medicine · 2018Article
- Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.International journal of biological sciences · 2018Review
- Biomarker MicroRNAs for Diagnosis of Oral Squamous Cell Carcinoma Identified Based on Gene Expression Data and MicroRNA-mRNA Network Analysis.Computational and mathematical methods in medicine · 2017Article
- MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.Disease markers · 2017Article
- Knowledge-Guided Bioinformatics Model for Identifying Autism Spectrum Disorder Diagnostic MicroRNA Biomarkers.Scientific reports · 2016Article
- MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma.Oncotarget · 2016Article
- Long Non-coding RNAs in Urologic Malignancies: Functional Roles and Clinical Translation.Journal of Cancer · 2016Review
- Novel Biomarker MicroRNAs for Subtyping of Acute Coronary Syndrome: A Bioinformatics Approach.BioMed research international · 2016Article
- Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.Oncotarget · 2015Article
- Article
- MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition.Oncotarget · 2015Article
- Article
- Discovery and characterization of long intergenic non-coding RNAs (lincRNA) module biomarkers in prostate cancer: an integrative analysis of RNA-Seq data.BMC genomics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are potential regulators that contribute to the pathogenesis of cancer. Microarray technologies have been widely used to characterize aberrant miRNA expression patterns in cancer. Nevertheless, the miRNAs expression signatures identified for a same cancer differs among laboratories due to the cancer heterogeneity. In addition, how the deregulated miRNAs coordinately contribute to the tumourigenic process of prostate cancer remains elusive.
resultsWe evaluated five outlier detection algorithms that take into account the heterogeneity of cancer samples. ORT was selected as the best method and applied to four prostate cancer associated microRNA expression datasets. After microRNA target prediction and pathway enrichment mapping, 38 Gene Ontology terms, 16 KEGG pathways and 99 GeneGO pathways are found putative prostate cancer associated. Comparison with our previous studies, we identified two putative novel pathways important in prostate cancer. The two novel pathways are 1) ligand-independent activation of ESR1 and ESR2 and 2) membrane-bound ESR1: interaction with growth factors signalling.
conclusionsWe proved that expression signatures of at the pathway level well address the cancer heterogeneity and are more consistent than at the miRNA/gene levels. Based on this observation, we identified putative novel microRNA regulatory pathways which will help us to elucidate the cooperative function of different microRNAs in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.